Which is the eligible patient to be treated with pioglitazone? The expert view

J Endocrinol Invest. 2011 Nov;34(10):781-7. doi: 10.1007/BF03346725.

Abstract

Pioglitazone has an important role in the treatment of patients with Type 2 diabetes. The drug can help patients to achieve sustained glycemic control and may delay the requirement for insulin. Pioglitazone may provide benefits beyond its effects on glycemia, with data suggesting it may confer anti-atherosclerotic and cardioprotective properties. Attention should be given to possible side effects relating to class effects of TZD, and selection of appropriate patients to be prescribed pioglitazone will enable optimum benefits to be derived from pioglitazone treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Algorithms
  • Animals
  • Atherosclerosis / prevention & control
  • Blood Glucose / drug effects
  • Cardiotonic Agents / therapeutic use
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Insulin / therapeutic use
  • Insulin Resistance
  • Pioglitazone
  • Thiazolidinediones / adverse effects
  • Thiazolidinediones / therapeutic use*

Substances

  • Blood Glucose
  • Cardiotonic Agents
  • Hypoglycemic Agents
  • Insulin
  • Thiazolidinediones
  • Pioglitazone